MARKET

AFMD

AFMD

Affimed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.900
-0.040
-1.36%
After Hours: 2.900 0 0.00% 16:00 01/24 EST
OPEN
3.010
PREV CLOSE
2.940
HIGH
3.050
LOW
2.860
VOLUME
661.02K
TURNOVER
--
52 WEEK HIGH
4.680
52 WEEK LOW
2.180
MARKET CAP
186.15M
P/E (TTM)
-15.7438
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AFMD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AFMD News

  • Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer
  • GlobeNewswire.01/10 11:30
  • Edited Transcript of AFMD earnings conference call or presentation 19-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.01/07 15:39
  • New additions to NASDAQ Biotechnology index
  • seekingalpha.12/17/2019 18:56
  • Affimed Announces Addition to NASDAQ Biotechnology Index
  • GlobeNewswire.12/17/2019 12:30

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About AFMD

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
More

Webull offers Affimed NV (AFMD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.